Skip to main content

Insulet Corporation stock price and financials

  • PODD · Nasdaq
  • Medical devices
  • Health Care Equipment
  • S&P 500
$152.48+2.14%Close 13 Nov 2026
EV / EBITDA
15.80
Beta · 1 year
0.44
Return · 1 year
−54.7%
52-week range$126.40 — $354.88

Share price close 16 Nov 2026

+5.9%1 monthHigh $165.02Low $141.10
$140$150$160$170Q3 FY2026 report filed 4 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
−0.3%6 monthsHigh $170.62Low $130.47
$120$140$160$180Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
−48.3%year to dateHigh $299.17Low $130.47
$100$150$200$250$300Q4 FY2025 report filed 18 Feb 2026Q1 FY2026 report filed 6 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
−55.8%1 yearHigh $346.36Low $130.47
$100$200$300$400Q4 FY2025 report filed 18 Feb 2026Q1 FY2026 report filed 6 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
−15.3%3 yearsHigh $352.82Low $130.47
$100$200$300$400Q4 FY2023 report filed 23 Feb 2024Q1 FY2024 report filed 10 May 2024Q2 FY2024 report filed 9 Aug 2024Q3 FY2024 report filed 8 Nov 2024Q4 FY2024 report filed 21 Feb 2025Q1 FY2025 report filed 9 May 2025Q2 FY2025 report filed 7 Aug 2025Q3 FY2025 report filed 6 Nov 2025Q4 FY2025 report filed 18 Feb 2026Q1 FY2026 report filed 6 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+295%10 yearsHigh $352.82Low $33.32
$0$100$200$300$400Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Insulet Corporation reported revenue of $2.71 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 30.7% from fiscal 2024. Net income was $247 million and diluted earnings per share $3.48.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $842 million, up 19.2% from a year earlier.

Figures from Insulet Corporation's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026.

Revenue FY2025
$2.71B+30.7%
Net income
$247.1M−40.9%
Diluted EPS
$3.48−39.8%
Gross margin
71.6%+1.8 pts
Free cash flow
$377.7M+23.7%
Net debt
$285.0M−39.2%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$1B$0$1B$2B$3BRevenue, FY16: $366.99MNet income, FY16: −$28.88MFY16Revenue, FY17: $463.8MNet income, FY17: −$26.8MFY17Revenue, FY18: $563.8MNet income, FY18: $3.3MFY18Revenue, FY19: $738.2MNet income, FY19: $11.6MFY19Revenue, FY20: $904.4MNet income, FY20: $6.8MFY20Revenue, FY21: $1.1BNet income, FY21: $16.8MFY21Revenue, FY22: $1.31BNet income, FY22: $4.6MFY22Revenue, FY23: $1.7BNet income, FY23: $206.3MFY23Revenue, FY24: $2.07BNet income, FY24: $418.3MFY24Revenue, FY25: $2.71BNet income, FY25: $247.1MFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 4 Nov 2026 · Full results →

Revenue
$842.0M+19.2% on a year
Gross margin
75.1%+2.8 pts on a year
Operating income
$189.8M+61.3% on a year
Net income
$141.1M+61.1% on a year
Diluted EPS
$2.03+63.7% on a year
Free cash flow
$66.40M−33.7% on a year

Comparable companies All of Health Care →

Insulet Corporation beside the other S&P 500 members in Health Care Equipment, by market value.

Insulet Corporation and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Insulet CorporationPODD—+2.1%−54.7%———
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-50%0%50%100%71.6%17.5%9.1%FY16FY19FY22FY25

Insulet Corporation revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By product

Insulet Corporation revenue by product, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
U.S.$651.5M$884.8M+35.8%$1.25B+41.4%$1.51B+20.6%$1.92B+27.2%
International$359.9M$363.0M+0.9%$410.1M+13.0%$523.4M+27.6%$754.3M+44.1%
Drug Delivery$87.40M$57.50M−34.2%$36.00M−37.4%$38.90M+8.1%$34.10M−12.3%
Total revenue$1.10B$1.31B$1.70B$2.07B$2.71B

By country

Insulet Corporation revenue by country, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$738.9M$942.3M+27.5%$1.29B+36.6%$1.55B+20.3%$1.95B+26.2%
International$359.9M$363.0M+0.9%$410.1M+13.0%$523.4M+27.6%$754.3M+44.1%
Total revenue$1.10B$1.31B$1.70B$2.07B$2.71B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Insulet Corporation income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$367.0M$463.8M$563.8M$738.2M$904.4M$1.10B$1.31B$1.70B$2.07B$2.71B
Revenue growth+39.1%+26.4%+21.6%+30.9%+22.5%+21.5%+18.8%+30.0%+22.1%+30.7%
Gross profit$211.1M$277.2M$370.2M$480.3M$582.3M$752.1M$805.6M$1.16B$1.45B$1.94B
Operating income−$10.70M−$7.40M$27.40M$50.00M$51.50M$126.0M$37.60M$220.1M$308.9M$473.8M
Net income−$28.88M−$26.80M$3.30M$11.60M$6.80M$16.80M$4.60M$206.3M$418.3M$247.1M
Diluted EPS−$0.48−$0.46$0.05$0.19$0.10$0.24$0.07$2.94$5.78$3.48
Gross margin57.5%59.8%65.7%65.1%64.4%68.4%61.7%68.3%69.8%71.6%
Operating margin−2.9%−1.6%4.9%6.8%5.7%11.5%2.9%13.0%14.9%17.5%
Net margin−7.9%−5.8%0.6%1.6%0.8%1.5%0.4%12.2%20.2%9.1%

Cash flow

Insulet Corporation cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$15.91M$41.30M$35.90M$98.40M$84.00M−$68.10M$119.0M$145.7M$430.2M$569.3M
Capital expenditure$22.11M$73.80M$157.4M$163.7M$129.0M$111.9M$122.9M$75.60M$124.9M$191.6M
Free cash flow−$6.20M−$32.50M−$121.5M−$65.30M−$45.00M−$180.0M−$3.90M$70.10M$305.3M$377.7M

Balance sheet and shares

Insulet Corporation balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$137.2M$272.6M$113.9M$213.7M$907.2M$806.4M$689.7M$704.2M$953.4M$716.1M
Total debt$332.8M$566.2M$592.0M$905.9M$1.08B$1.29B$1.43B$1.45B$1.42B$1.00B
Shareholders' equity$63.15M$158.5M$212.1M$75.90M$603.6M$556.3M$476.4M$732.7M$1.21B$1.52B
Diluted shares57.3M58.0M61.0M62.3M65.9M68.6M69.9M73.6M73.9M71.9M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Insulet Corporation quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$597.5M$569.0M$649.1M$706.3M$783.8M$761.7M$801.7M$842.0M
Revenue, year on year+17.2%+28.8%+32.9%+29.9%+31.2%+33.9%+23.5%+19.2%
Gross margin72.1%71.9%69.7%72.2%72.5%69.5%70.2%75.1%
Operating income$109.3M$88.80M$121.1M$117.7M$146.3M$122.1M$129.7M$189.8M
Net income$100.7M$35.40M$22.50M$87.60M$101.6M$91.10M$95.00M$141.1M
Diluted EPS$1.39$0.50$0.32$1.24$1.44$1.30$1.37$2.03
Free cash flow$94.00M$51.50M$177.9M$100.1M$48.20M$89.50M$55.90M$66.40M

Operating KPIs

The operating figures Insulet Corporation reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Insulet Corporation operating KPIs
KPILatestPeriodChange on a yearRecent periods
U.S. revenue$570.4Mquarter to 30 Sep 2026up 14.7%
International revenue$266.2Mquarter to 30 Sep 2026up 31.7%
Drug Delivery revenue$5.5Mquarter to 30 Sep 2026down 22.5%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Insulet Corporation's revenue in fiscal 2025?

$2.71 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Insulet Corporation's net income in fiscal 2025?

$247 million for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Insulet Corporation's diluted earnings per share in fiscal 2025?

$3.48 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Insulet Corporation's gross margin?

71.6% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Insulet Corporation's operating margin?

17.5% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Insulet Corporation generate in fiscal 2025?

$378 million for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Insulet Corporation's revenue come from?

In fiscal 2025, by product: U.S. $1.92B (71%), International $754.3M (28%), Drug Delivery $34.10M (1.3%), out of $2.71B in all, as stated in its annual report.

In the terminal

Twenty years of Insulet Corporation's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans